Truist Securities Rates Evolent Health (EVH) buy, $7 Price Target
Truist Securities has reiterated its buy rating on Evolent Health, setting a target price of $7.0, a 48.78% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Evolent Health, Inc. ($EVH) "buy" with a $7 price target on June 12, 2026.
Since the rating, $EVH is down 6.7% after 1 week, up 23.3% after 1 month and down 4.8% to date (from the $4.80 close on Jun 12, 2026).
EVH
Evolent Health, Inc.
Key Points
- Truist Securities reiterated its buy rating on Evolent Health, targeting $7.0, with shares priced at $4.71 on June 12, 2026.
- Truist Securities's $7 price target implies 48.78% upside from Evolent Health, Inc.'s ($EVH) current $4.71 share price.
- The stock trades significantly below its 52-week high of $9.63, suggesting room for growth as analysts remain optimistic.
- Evolent Health has a forward P/E ratio of 9.44 and is expected to report earnings on November 5, 2026.
Get $EVH trade alerts by text
We text you when insiders, Congress or big funds trade $EVH. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Evolent Health, Inc. alert may contain errors. Disclosures
Truist Securities Sticks with Buy Rating
Truist Securities has reiterated its buy rating on Evolent Health, Inc. (NYSE: EVH) with a target price of $7.0. This decision comes as the stock was priced at $4.71 on June 12, 2026. The firm believes in the company's potential despite its current trading position.
Comparing Wall Street Ratings
Truist's latest call aligns with a generally positive outlook from other analysts. For instance, JP Morgan maintains an Overweight rating with a target of $6.0, while TD Cowen also keeps a Buy rating with a $6.0 target. Citigroup upgraded its view to Buy with a $6.0 target following a downgrade earlier in July. This suggests that many analysts see Evolent Health as undervalued at its current price.
Stock Performance Context
The stock has been fluctuating below its 52-week high of $9.63 and is currently trading near its 50-day moving average of $4.38. With a market cap of about $417.2 million, Evolent Health's shares have potential for upside if they can reach analysts' targets.
$EVH price target
Evolent Health, Inc. daily closes and this analyst's $7 target. Not advice.
What Evolent Health, Inc. Does
Evolent Health, Inc. provides specialty care management services across various medical fields, including oncology and cardiology. The company aims to enhance health plan administration through its integrated care management platform, making its performance closely watched by investors.
What’s Next for Evolent Health
Evolent Health is set to report its next earnings on November 5, 2026. As analysts continue to monitor its performance, the upcoming earnings report could provide further insights into its growth and operational health.
Related Filing Alerts
Source: Truist Securities's rating change on $EVH (Jun 12, 2026). Written by software, not financial advice. How we make alerts